# EDGAR Filing Document

**Accession Number:** 0001779128
**File Stem:** 0001628280-26-031032
**Filing Date:** 2026-5
**Character Count:** 156700
**Document Hash:** 4f19913e0e864492574c9865eb96b55d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-031032.hdr.sgml**: 20260506

**ACCESSION NUMBER**: 0001628280-26-031032

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 80

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260506

**DATE AS OF CHANGE**: 20260506

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Strata Critical Medical, Inc.
- **CENTRAL INDEX KEY:** 0001779128
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-HEALTH SERVICES [8000]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 841890381
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39046
- **FILM NUMBER:** 26947058

**BUSINESS ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-967-1009

**MAIL ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE
- **STREET 2:** 25TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Blade Air Mobility, Inc.
- **DATE OF NAME CHANGE:** 20210507

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Experience Investment Corp.
- **DATE OF NAME CHANGE:** 20190606

?xml version='1.0' encoding='ASCII'? blde-20260331

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

499E

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**Form 10-Q**

**(Mark One)**

⌧ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended: March 31, 2026**

**OR**

□ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.**

**For the transition period from &nbsp;&nbsp;&nbsp;&nbsp;to** 

Commission File Number **001-39046**

**STRATA CRITICAL MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **84-1890381** |
| (State or other jurisdiction<br>of incorporation or organization) | (I.R.S.Employer<br>Identification No.) |
| **666 Third Avenue, 25th Floor**<br>**New York, NY** | **10017** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| **(917) 781-3190** |
| (Registrant's telephone number, including area code) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on**<br>**which registered** |
| Common Stock, $0.0001 par value per share | SRTA | The Nasdaq Stock Market |
| Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share | SRTAW | The Nasdaq Stock Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧ No □

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S–T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧ No □

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non–accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," " smaller reporting company," and "emerging growth company" in Rule 12b–2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | ⌧ |
| Non-accelerated filer | □ | Smaller reporting company | □ |
| Emerging growth company | □ | | |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b–2 of the Exchange Act). Yes □ No ⌧

As of April 27, 2026, there were 86,526,570 shares of the registrant's Common Stock, $0.0001 par value per share, issued and outstanding.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**FORM 10-Q**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| | | Page |
| <u>[PART I. FINANCIAL INFORMATION](#i478d476b6c9945bc916cef5843252416_352)</u> | <u>[PART I. FINANCIAL INFORMATION](#i478d476b6c9945bc916cef5843252416_352)</u> | [3](#i478d476b6c9945bc916cef5843252416_352) |
| &nbsp;&nbsp;<u>[Item 1.](#i478d476b6c9945bc916cef5843252416_355)</u> | <u>[Financial statements](#i478d476b6c9945bc916cef5843252416_355)</u> | [3](#i478d476b6c9945bc916cef5843252416_355) |
|  | <u>[Unaudited Interim Condensed Consolidated Balance Sheets as of](#i478d476b6c9945bc916cef5843252416_178)[March 31,](#i478d476b6c9945bc916cef5843252416_178)[2](#i478d476b6c9945bc916cef5843252416_178)[02](#i478d476b6c9945bc916cef5843252416_178)[6](#i478d476b6c9945bc916cef5843252416_178)[and December 31, 202](#i478d476b6c9945bc916cef5843252416_178)[5](#i478d476b6c9945bc916cef5843252416_178)</u> | [3](#i478d476b6c9945bc916cef5843252416_178) |
|  | <u>[Unaudited Interim](#i478d476b6c9945bc916cef5843252416_181)[Condensed](#i478d476b6c9945bc916cef5843252416_178)[Consolidated Statements of Operations for the three](#i478d476b6c9945bc916cef5843252416_181)[months ended](#i478d476b6c9945bc916cef5843252416_181)[March](#i478d476b6c9945bc916cef5843252416_181)[3](#i478d476b6c9945bc916cef5843252416_181)[1](#i478d476b6c9945bc916cef5843252416_181)[, 202](#i478d476b6c9945bc916cef5843252416_181)[6](#i478d476b6c9945bc916cef5843252416_181)[and](#i478d476b6c9945bc916cef5843252416_181)[2025](#i478d476b6c9945bc916cef5843252416_181)</u> | [4](#i478d476b6c9945bc916cef5843252416_184) |
|  | <u>[Unaudited Interim](#i478d476b6c9945bc916cef5843252416_187)[Condensed](#i478d476b6c9945bc916cef5843252416_178)[Consolidated Statements of Comprehensive Income (Loss) for the three](#i478d476b6c9945bc916cef5843252416_187)[months ended](#i478d476b6c9945bc916cef5843252416_187)[March 31, 2026](#i478d476b6c9945bc916cef5843252416_187)[and](#i478d476b6c9945bc916cef5843252416_187)[2025](#i478d476b6c9945bc916cef5843252416_187)</u> | [5](#i478d476b6c9945bc916cef5843252416_187) |
|  | <u>[Unaudited Interim](#i478d476b6c9945bc916cef5843252416_190)[Condensed](#i478d476b6c9945bc916cef5843252416_178)[Consolidated Statements of Stockholders' Equity for the three](#i478d476b6c9945bc916cef5843252416_190)[months ended](#i478d476b6c9945bc916cef5843252416_190)[March 31,](#i478d476b6c9945bc916cef5843252416_190)[202](#i478d476b6c9945bc916cef5843252416_190)[6](#i478d476b6c9945bc916cef5843252416_190)[and 202](#i478d476b6c9945bc916cef5843252416_190)[5](#i478d476b6c9945bc916cef5843252416_190)</u> | [6](#i478d476b6c9945bc916cef5843252416_190) |
|  | <u>[Unaudited Interim](#i478d476b6c9945bc916cef5843252416_199)[Condensed](#i478d476b6c9945bc916cef5843252416_178)[Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and](#i478d476b6c9945bc916cef5843252416_199)[202](#i478d476b6c9945bc916cef5843252416_181)[5](#i478d476b6c9945bc916cef5843252416_181)</u> | [7](#i478d476b6c9945bc916cef5843252416_199) |
|  | <u>[Notes to Unaudited Interim](#i478d476b6c9945bc916cef5843252416_202)[Condensed](#i478d476b6c9945bc916cef5843252416_178)[Consolidated Financial Statements](#i478d476b6c9945bc916cef5843252416_202)</u> | [8](#i478d476b6c9945bc916cef5843252416_202) |
| &nbsp;&nbsp;<u>[Item 2.](#i478d476b6c9945bc916cef5843252416_358)</u> | <u>[Management's discussion and analysis of financial condition and results of operations](#i478d476b6c9945bc916cef5843252416_358)</u> | [23](#i478d476b6c9945bc916cef5843252416_358) |
| &nbsp;&nbsp;<u>[Item 3.](#i478d476b6c9945bc916cef5843252416_364)</u> | <u>[Quantitative and qualitative disclosures about market risk](#i478d476b6c9945bc916cef5843252416_364)</u> | [37](#i478d476b6c9945bc916cef5843252416_364) |
| &nbsp;&nbsp;<u>[Item 4.](#i478d476b6c9945bc916cef5843252416_367)</u> | <u>[Controls and procedures](#i478d476b6c9945bc916cef5843252416_367)</u> | [37](#i478d476b6c9945bc916cef5843252416_367) |
| <u>[PART II. OTHER INFORMATION](#i478d476b6c9945bc916cef5843252416_370)</u> | <u>[PART II. OTHER INFORMATION](#i478d476b6c9945bc916cef5843252416_370)</u> | [38](#i478d476b6c9945bc916cef5843252416_370) |
| &nbsp;&nbsp;<u>[Item 1.](#i478d476b6c9945bc916cef5843252416_37)</u> | <u>[Legal proceedings](#i478d476b6c9945bc916cef5843252416_373)</u> | [38](#i478d476b6c9945bc916cef5843252416_373) |
| &nbsp;&nbsp;<u>[Item 1A.](#i478d476b6c9945bc916cef5843252416_376)</u> | <u>[Risk factors](#i478d476b6c9945bc916cef5843252416_376)</u> | [38](#i478d476b6c9945bc916cef5843252416_376) |
| &nbsp;&nbsp;<u>[Item 2.](#i478d476b6c9945bc916cef5843252416_379)</u> | <u>[Unregistered sales of equity securities, use of proceeds and Issuer purchases of equity securities](#i478d476b6c9945bc916cef5843252416_379)</u> | [38](#i478d476b6c9945bc916cef5843252416_379) |
| &nbsp;&nbsp;<u>[Item 3.](#i478d476b6c9945bc916cef5843252416_382)</u> | <u>[Defaults upon senior securities](#i478d476b6c9945bc916cef5843252416_382)</u> | [38](#i478d476b6c9945bc916cef5843252416_382) |
| &nbsp;&nbsp;<u>[Item 4.](#i478d476b6c9945bc916cef5843252416_385)</u> | <u>[Mine safety disclosures](#i478d476b6c9945bc916cef5843252416_385)</u> | [38](#i478d476b6c9945bc916cef5843252416_385) |
| &nbsp;&nbsp;<u>[Item 5.](#i478d476b6c9945bc916cef5843252416_388)</u> | <u>[Other information](#i478d476b6c9945bc916cef5843252416_388)</u> | [38](#i478d476b6c9945bc916cef5843252416_388) |
| &nbsp;&nbsp;<u>[Item 6.](#i478d476b6c9945bc916cef5843252416_391)</u> | <u>[Exhibits](#i478d476b6c9945bc916cef5843252416_391)</u> | [39](#i478d476b6c9945bc916cef5843252416_391) |
| <u>[SIGNATURES](#i478d476b6c9945bc916cef5843252416_394)</u> | <u>[SIGNATURES](#i478d476b6c9945bc916cef5843252416_394)</u> | [40](#i478d476b6c9945bc916cef5843252416_394) |

---

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**PART I. FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**STRATA CRITICAL MEDICAL, INC.** 

**Unaudited Interim Condensed Consolidated Balance Sheets**

*(in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | **March 31,<br>2026** | **December 31,<br>2025** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;Cash and cash equivalents | $58723 | $30968 |
| &nbsp;&nbsp;Restricted cash | 264 | 264 |
| &nbsp;&nbsp;Accounts receivable, net of allowance of $1,007 and $1,066 at March 31, 2026 and December 31, 2025, respectively | 39602 | 39958 |
| &nbsp;&nbsp;Short-term investments | 66 | 30263 |
| &nbsp;&nbsp;Prepaid expenses and other current assets | 25490 | 24739 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 124145 | 126192 |
| Non-current assets: |  |  |
| &nbsp;&nbsp;Property and equipment, net | 40087 | 36444 |
| &nbsp;&nbsp;Intangible assets, net | 46312 | 47502 |
| &nbsp;&nbsp;Goodwill | 88589 | 88210 |
| &nbsp;&nbsp;Operating right-of-use asset | 4195 | 3107 |
| &nbsp;&nbsp;Other non-current assets | 24290 | 24017 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $327618 | $325472 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;Accounts payable and accrued expenses | $19955 | $19142 |
| &nbsp;&nbsp;Operating lease liability, current | 987 | 652 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 20942 | 19794 |
| Non-current liabilities: |  |  |
| &nbsp;&nbsp;Warrant liability | 71 | 1530 |
| &nbsp;&nbsp;Operating lease liability, long-term | 3481 | 2655 |
| &nbsp;&nbsp;Deferred tax liability | 271 | 348 |
| &nbsp;&nbsp;Other non-current liabilities | 17122 | 22073 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 41887 | 46400 |
| Commitments and Contingencies (Note 12) |  |  |
| **Stockholders' Equity** |  |  |
| &nbsp;&nbsp;Preferred stock, $0.0001 par value, 2,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively |  |  |
| Common stock, $0.0001 par value; 400,000,000 authorized; 86,521,570 and 86,702,183 shares issued at March 31, 2026 and December 31, 2025, respectively | 7 | 7 |
| &nbsp;&nbsp;Additional paid in capital | 429121 | 424616 |
| &nbsp;&nbsp;Accumulated other comprehensive income |  |  |
| &nbsp;&nbsp;Accumulated deficit | (143397) | (145551) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 285731 | 279072 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $327618 | $325472 |

---

*See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Operations**

*(in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue | $67384 | $35948 |
| &nbsp;&nbsp;Cost of revenue | 53267 | 28895 |
| Gross profit | 14117 | 7053 |
| Operating expenses |  |  |
| &nbsp;&nbsp;Selling, general and administrative | 15605 | 12330 |
| &nbsp;&nbsp;Amortization of intangible assets | 1486 | 408 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 17091 | 12738 |
| Operating loss from continuing operations | (2974) | (5685) |
| Other non-operating income |  |  |
| &nbsp;&nbsp;Interest income, net | 473 | 1321 |
| &nbsp;&nbsp;Change in fair value of warrant liabilities | 1459 | 2752 |
| &nbsp;&nbsp;Change in fair value of assets and other liabilities | 3444 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other non-operating income | 5376 | 4073 |
| Income (loss) from continuing operations before income taxes | 2402 | (1612) |
| &nbsp;&nbsp;Income tax expense from continuing operations |  |  |
| Net income (loss) from continuing operations | 2402 | (1612) |
| &nbsp;&nbsp;Net loss from discontinued operations | (248) | (1881) |
| Net income (loss) | $2154 | $(3493) |
| Basic earnings (loss) per share |  |  |
| &nbsp;&nbsp;Continuing operations | $0.03 | $(0.02) |
| &nbsp;&nbsp;Discontinued operations |  | (0.02) |
| Total basic earnings (loss) per share | $0.03 | $(0.04) |
| Diluted earnings (loss) per share |  |  |
| &nbsp;&nbsp;Continuing operations | $0.03 | $(0.02) |
| &nbsp;&nbsp;Discontinued operations |  | (0.02) |
| Total diluted earnings (loss) per share | $0.03 | $(0.04) |
| Weighted-average number of shares outstanding: |  |  |
| &nbsp;&nbsp;Basic | 85322941 | 79891829 |
| &nbsp;&nbsp;Diluted | 90168853 | 79891829 |

---

 *See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Comprehensive Income (Loss)**

*(in thousands)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Net income (loss) | $2154 | $(3493) |
| Other comprehensive income (loss): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Foreign currency translation adjustments |  | 1316 |
| Other comprehensive income |  | 1316 |
| Comprehensive income (loss) | $2154 | $(2177) |

---

 *See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Stockholders' Equity** 

*(in thousands, except share data)*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Common Stock** | **Common Stock** | **Additional Paid-In Capital** | **Accumulated Other Comprehensive Income** | **Accumulated<br>Deficit** | **Total<br>Stockholders'<br>Equity** |
| | **Shares** | **Amount** | **Additional Paid-In Capital** | **Accumulated Other Comprehensive Income** | **Accumulated<br>Deficit** | **Total<br>Stockholders'<br>Equity** |
| **Balance as of January 1, 2026** | **86702183** | $**7** | $**424616** | $**—** | $**(145551)** | $**279072** |
| Issuance of common stock upon exercise of stock options | 286960 |  | 52 |  |  | 52 |
| Issuance of common stock upon settlement of restricted stock units | 336098 |  |  |  |  |  |
| Stock-based compensation - restricted stock |  |  | 5035 |  |  | 5035 |
| Shares withheld related to net share settlement | (128337) |  | (582) |  |  | (582) |
| Retirement of common stock | (675334) |  |  |  |  |  |
| Net income |  |  |  |  | 2154 | 2154 |
| **Balance as of March 31, 2026** | **86521570** | $**7** | $**429121** | $**—** | $**(143397)** | $**285731** |
| **Balance as of January 1, 2025** | **79419028** | $**7** | $**407076** | $**1753** | $**(186898)** | $**221938** |
| Issuance of common stock upon exercise of stock options | 1568167 |  | 60 |  |  | 60 |
| Issuance of common stock upon settlement of restricted stock units | 1465407 |  |  |  |  |  |
| Stock-based compensation - restricted stock |  |  | 4217 |  |  | 4217 |
| Shares withheld related to net share settlement | (1478968) |  | (4306) |  |  | (4306) |
| Other comprehensive income |  |  |  | 1316 |  | 1316 |
| Net loss |  |  |  |  | (3493) | (3493) |
| **Balance as of March 31, 2025** | **80973634** | $**7** | $**407047** | $**3069** | $**(190391)** | $**219732** |

---

*See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Unaudited Interim Condensed Consolidated Statements of Cash Flows**

*(in thousands)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Cash Flows From Operating Activities:** |  |  |
| Net income / (loss) | $2154 | $(3493) |
| &nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash and restricted cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in gain on sale of business | 344 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 3060 | 1697 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation | 5035 | 4217 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant liabilities | (1459) | (2752) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of other assets and liabilities | (3444) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accretion of interest income on held-to-maturity securities | (265) | (723) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred tax expense | (77) | (17) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | 27 | 93 |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 383 | 2254 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 149 | (520) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | 78 | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating right-of-use assets/lease liabilities | 73 | (30) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | (2158) | (2278) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred revenue | (3) | 1293 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | (12) |  |
| **Net cash provided by/ (used in) operating activities** (*includes discontinued operations; see Note 4)* | 3885 | (246) |
| **Cash Flows From Investing Activities:** |  |  |
| &nbsp;&nbsp;Cash transfer related to sale of business | (290) |  |
| &nbsp;&nbsp;Capitalized software development costs | (302) | (532) |
| &nbsp;&nbsp;Purchase of property and equipment, net of proceeds from disposal | (5179) | (2614) |
| &nbsp;&nbsp;Purchase of held-to-maturity investments |  | (84197) |
| &nbsp;&nbsp;Proceeds from maturities of held-to-maturity investments | 30500 | 107750 |
| **Net cash provided by investing activities (***includes discontinued operations; see Note 4*) | 24729 | 20407 |
| **Cash Flows From Financing Activities:** |  |  |
| &nbsp;&nbsp;Proceeds from the exercise of common stock options | 52 | 60 |
| &nbsp;&nbsp;Taxes paid related to net share settlement of equity awards | (582) | (4306) |
| &nbsp;&nbsp;Payments for debt issuance costs | (329) |  |
| **Net cash used in financing activities (***includes discontinued operations; see Note 4***)** | (859) | (4246) |
| Effect of foreign exchange rate changes on cash balances |  | 126 |
| **Net increase in cash and cash equivalents and restricted cash** | 27755 | 16041 |
| **Cash and cash equivalents and restricted cash - beginning** | 31232 | 19647 |
| **Cash and cash equivalents and restricted cash - ending** | $58987 | $35688 |
| **Reconciliation to consolidated balance sheets** (*includes discontinued operations; see Note 4)* |  |  |
| Cash and cash equivalents | $58723 | $34830 |
| Restricted cash | 264 | 858 |
| Total cash and cash equivalents and restricted cash | $58987 | $35688 |
| **Supplemental cash flow information** |  |  |
| &nbsp;&nbsp;Non-cash investing and financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;New leases under ASC 842 entered into during the period | $1317 | $608 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment and capitalized software in accounts payable and accrued expenses | 161 | 339 |

---

 *See Notes to Unaudited Interim Condensed Consolidated Financial Statements.*

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

**Note 1 – Description of Business and Summary of Significant Accounting Policies**

***Description of Business***

Strata Critical Medical, Inc. ("Strata" or the "Company") is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation's largest air transport and surgical services networks for transplant hospitals and Organ Procurement Organizations ("OPOs"), offering an integrated "one call" solution for donor organ recovery. Strata's core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions ("Trinity") and Keystone Perfusion brands.

Strata's mission is to increase the number of organs that are successfully transplanted while leveraging the Company's expertise and resources to provide other medical and logistics services to a broader customer base. Strata's goals are closely aligned with those of all participants in the transplant ecosystem, including transplant centers, regulators, OPOs and other service providers.

On August 29, 2025, the Company completed the sale of its Passenger business to Joby Aero, Inc. ("Joby Buyer"), a wholly owned subsidiary of Joby Aviation, Inc. ("Joby Aviation"). The sale followed the separation of the Company's Passenger business, which provided air and ground transportation services for passengers on third-party aircraft, from the Company's remaining medical operations.

On September 16, 2025, the Company completed the acquisition of Keystone Perfusion Services, LLC, a Pennsylvania limited liability company ("Keystone"), an organ recovery and normothermic regional perfusion service provider to the transplant industry, pursuant to a Purchase and Sale Agreement, dated September 16, 2025 (the "Keystone Purchase Agreement").

***Basis of Presentation and Principles of Consolidation***

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Management's opinion is that all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of financial position, results of operations and cash flows at the dates and for the periods presented have been included. Operating results for the three months ended March 31, 2026 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2026. These financial statements should be read in conjunction with the Company's consolidated financial statements and accompanying Notes included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

As discussed above, on August 29, 2025, the Company completed the previously announced sale of its Passenger business to Joby Buyer. The results of the Passenger business are presented as discontinued operations in the accompanying unaudited interim condensed consolidated statement of operations for all periods presented.

Certain prior year amounts have been reclassified to conform to the current period presentation. These reclassified amounts had no impact on our previously reported results of operations or net cash flows from operating, financing or investing activities.

***Short-Term Investments***

*Held-to-Maturity Securities*

The Company's investments in held-to-maturity securities consist of investment grade U.S. Treasury obligations with maturity dates of less than 365 days. The Company has the ability and intention to hold these securities until maturity. Accordingly, these securities are recorded in the Company's unaudited interim condensed consolidated balance sheet at amortized cost and interest is recorded within interest income on the Company's unaudited interim condensed consolidated statement of operations. As of March 31, 2026, all held-to-maturity securities had matured, the remaining balance of $66

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

represents accrued interest receivable. The held-to-maturity securities balance and fair market value at December 31, 2025 were $30,263 and $30,281, respectively. The held-to-maturity securities gross unrealized holding loss as of March 31, 2025 was $5. The fair value hierarchy of the valuation inputs the Company utilized to determine such fair market value is Level 2.

***Concentrations***

Financial instruments which potentially subject the Company to concentrations of credit risk consists principally of cash amounts on deposit with financial institutions. At times, the Company's cash in banks is in excess of the Federal Deposit Insurance corporation ("FDIC") insurance limit. The Company has not experienced any loss as a result of these deposits.

*Major Customers*

No single customer accounted for 10% or more of the Company's revenue for the three months ended March 31, 2026. One national hospital group—comprised of three customers, each under a separate contract—accounted for approximately 13% of the Company's revenue for the three months ended March 31, 2025.

No single customer accounted for 10% or more of the Company's outstanding accounts receivable as of March 31, 2026. No single customer accounted for 10% or more of the Company's outstanding accounts receivable as of December 31, 2025.

*Major Vendors*

One vendor accounted for 12% of the Company's purchases from operating vendors for the three months ended March 31, 2026. Two vendors accounted for 20% and 10%, respectively, of the Company's purchases from operating vendors for the three months ended March 31, 2025.

Two vendors accounted for 16% and 11%, respectively, of the Company's outstanding accounts payable as of March 31, 2026. One vendor accounted for 12% of the Company's outstanding accounts payable as of December 31, 2025.

***Property and Equipment, Net***

---

| | | | |
|:---|:---|:---|:---|
| | **Useful Life** <br>**(in years)** | **March 31,<br>2026** | **December 31,<br>2025** |
| Aircraft, engines and related rotable parts (1) | 2 - 20 | $37017 | $32454 |
| Vehicles (1) | 5 | 4178 | 4078 |
| Leasehold improvements (2) | Shorter of useful life or life of lease | 901 | 835 |
| Furniture and fixtures (2) | 5 | 533 | 391 |
| Technology equipment (2) | 3 | 158 | 64 |
| Medical and other machinery equipment (1) | 5 | 5160 | 4908 |
| Total property and equipment, gross |  | 47947 | 42730 |
| Less: Accumulated depreciation |  | (7860) | (6286) |
| Total property and equipment, net |  | $40087 | $36444 |

---

(1) Depreciation expense is included within cost of revenue.

(2) Depreciation expense is included within selling, general and administrative expenses.

For the three months ended March 31, 2026 and 2025, the Company recorded depreciation expense for property and equipment of $1,574 and $816, respectively. For the three months ended March 31, 2026, disposals of certain property and equipment were immaterial. For the three months ended March 31, 2025, the Company disposed of $61 in property and equipment and likewise wrote off previously recognized accumulated depreciation expense of $35.

***Use of Estimates***

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company's financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment evolves.

Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the financial statements. Significant estimates and assumptions by management include, but are not limited to, the fair value of contingent consideration, intangible assets, goodwill and stock-based payment liability-classified awards.

***Recently Issued Accounting Pronouncements - Adopted***

On January 1, 2026, we adopted ASU 2025-05, *Financial Instruments — Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets,* which provides a practical expedient allowing entities to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset when estimating expected credit losses on current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. The adoption of this standard did not have a material impact on our results of operations or financial position*.*

***Recently Issued Accounting Pronouncements - Not Adopted***

In October 2023, the FASB issued ASU 2023-06, *Disclosure Improvements.* The new guidance clarifies or improves disclosure and presentation requirements on a variety of topics in the codification. The amendments in the update are intended to align the requirements in the FASB ASC with the SEC's regulations. The amendments are effective prospectively on the date each individual amendment is effectively removed from Regulation S-X or Regulation S-K, or if the SEC has not removed the requirements by June 30, 2027, this amendment will be removed from the Codification and will not become effective for any entity. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses.* The ASU requires additional disclosure of the nature of expenses included in the income statement as well as disclosures about specific types of expenses included in the expense captions presented in the income statement as well as disclosures about selling expenses. The ASU is effective for annual periods beginning after December 15, 2026. Early adoption is permitted. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In January 2025, FASB issued ASU 2025-01, *Income Statement - Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40), Clarifying the Effective Date*. This ASU amends the effective date of ASU 2024-03 to clarify that all public business entities are required to adopt the guidance in annual reporting periods beginning after December 15, 2026. Early adoption of ASU 2024-03 is permitted. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, *Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software*. The ASU clarifies and modernizes the accounting for costs related to internal-use software. The ASU is effective for annual periods beginning after December 15, 2027, and interim reporting periods within those annual reporting periods. Early adoption is also permitted for annual or interim financial statements that have not yet been issued or made available for issuance. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-11, *Interim Reporting (Topic 270): Narrow-Scope Improvements*, which clarifies the guidance in Topic 270 to improve the consistency of interim financial reporting. The ASU provides a comprehensive list of required interim disclosures and introduces a disclosure principle requiring entities to disclose events

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

since the end of the last annual reporting period that have a material impact on the entity. The ASU is effective for fiscal years beginning after December 15, 2027, and interim reporting periods within those fiscal years. Early adoption is also permitted for annual or interim financial statements that have not yet been issued or made available for issuance. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

In December 2025, the FASB issued ASU 2025-12, *Codification Improvements*. The ASU makes targeted technical corrections and minor clarifications across numerous areas of the Codification. The amendments are generally not intended to result in significant changes for most entities. The ASU is effective for annual periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. The adoption method may vary on an issue-by-issue basis. Early adoption is also permitted for annual or interim financial statements that have not yet been issued or made available for issuance. The Company is in the process of evaluating the impact the adoption of this ASU will have on the financial statements and related disclosures.

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force) and the SEC have not had, or are not anticipated to have, a significant effect on the Company's unaudited interim condensed consolidated financial statements, both present and future.

**Note 2 – Revenue**

*Disaggregated Revenue*

Company disaggregates revenue from contracts with customers by service category, as management believes this presentation best depicts how the nature, amount, timing, and uncertainty of the Company's revenue and cash flows are affected by economic factors, as shown below:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Logistics: |  |  |
| &nbsp;&nbsp;Logistics | $47599 | $35948 |
| Clinical: |  |  |
| &nbsp;&nbsp;Transplant Clinical | $9839 | $— |
| &nbsp;&nbsp;Other Clinical | 9946 |  |
| Total Clinical | $19785 | $— |
| **Total revenue** | $67384 | $35948 |

---

**Note 3 – Goodwill**

***Goodwill***

The changes in the carrying value of goodwill are as follows:

---

| | |
|:---|:---|
| Goodwill balance, December 31, 2025 | $88210 |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjustment (1) | 379 |
| Goodwill balance, March 31, 2026 | $88589 |

---

(1) Represents a measurement period adjustment made during the three months ended March 31, 2026, reflecting adjustments to the acquired net assets of Keystone. For additional information, see Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

The goodwill balance presented above relates to continuing operations and arise from the Trinity Acquisition, the CJK Acquisition and the Keystone Acquisition.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

**Note 4 – Discontinued Operations**

***Passenger Business Divestiture***

On August 29, 2025, the Company completed the sale of its Passenger business to Joby Buyer pursuant to that certain Equity Purchase Agreement, dated as of August 1, 2025 (the "Joby Purchase Agreement"), among the Company, Strata Critical, Inc. (f/k/a Trinity Medical Intermediate II, Inc.), a wholly owned subsidiary of the Company, Blade Urban Air Mobility, LLC (f/k/a Blade Urban Air Mobility, Inc.), Joby Aviation and Joby Buyer, a wholly owned subsidiary of Joby Aviation. The Passenger business acquired by Joby Buyer consisted of the Company's business of offering, selling, promoting, marketing, planning, booking, brokering, coordinating and arranging the transportation of passengers on aircraft operated by other entities and related ground transportation services. At closing, the Company received consideration valued at approximately $75,357 (based on Joby Aviation's closing stock price of $14.15 on August 29, 2025), after giving effect to pre-closing adjustments, consisting of 5,325,585 shares of Joby Aviation's common stock, par value $0.0001 per share (the "Buyer Shares"). The Company subsequently sold the Buyer Shares for net proceeds of $70,163. The Company may also receive up to an additional $35,000, payable in cash or Buyer Shares at Joby Buyer's election, upon the achievement of certain financial performance and employee retention targets within 12 and 18 months, respectively, following the closing, as well as the release of up to $10,000 in indemnity holdbacks.

The Company determined that the sale of the Passenger business represented a strategic shift that will have a major effect on its operations and financial results. Accordingly, the sale is classified as discontinued operations in accordance with ASC 205-20. The results of operations for the three months ended March 31, 2025 reflect the financial results of the Passenger business as discontinued operations. There were no assets or liabilities of the Passenger business remaining as of March 31, 2026 or December 31, 2025.

During the three months ended March 31, 2026, the Company made a final post-closing net working capital adjustment payment of $290 to Joby Buyer pursuant to the terms of the Joby Purchase Agreement, representing the final settlement of all purchase price adjustments under the Joby Purchase Agreement.

As of March 31, 2026, the Company continues to carry amounts arising from the Passenger business sale on its unaudited interim condensed consolidated balance sheet, including: (i) contingent consideration of $13,420 classified within prepaid expenses and other current assets, representing the estimated fair value of the financial performance earn-out; (ii) contingent consideration for retention of $15,400 classified within other non-current assets; and (iii) indemnity holdbacks of $8,801 classified within other non-current assets. These amounts are remeasured at fair value at each reporting date, with subsequent changes in fair value recognized within continuing operations.

The following table summarizes the results of operations of the Passenger business which are presented as discontinued operations:

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Revenue | $— | $18358 |
| &nbsp;&nbsp;Cost of revenue |  | 14314 |
| Gross profit |  | 4044 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;Selling, general and administrative |  | 5685 |
| &nbsp;&nbsp;Amortization of intangible assets |  | 257 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses |  | 5942 |
| Operating loss |  | (1898) |
| Interest expense |  |  |
| Change in gain on sale and disposal of discontinued operations | (344) |  |
| Loss from discontinued operations before income taxes | (344) | (1898) |
| Income tax benefit on discontinued operations | (96) | (17) |
| Net loss from discontinued operations | $(248) | $(1881) |

---

The tax benefit for the three months ended March 31, 2026 is attributable to discrete tax effects of the passenger sale. The tax benefit in the 2025 period was attributed entirely to Blade Monaco.

The cash flows related to discontinued operations have not been segregated and are included in the unaudited interim condensed consolidated statements of cash flows. The following table presents depreciation and amortization, capital expenditures and other non-cash operating activities of the discontinued operations related to the Passenger business:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Depreciation and amortization | $— | $473 |
| Stock-based compensation |  | 402 |
| Change in gain on sale of Passenger business | (344) |  |

---

**Note 5 – Prepaid expenses and other current assets**

Prepaid expenses and other current assets consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Contingent consideration asset related to sale of business | $13420 | $12550 |
| Prepaid expenses | 5898 | 7182 |
| Other current assets | 6172 | 5007 |
|  | $25490 | $24739 |

---

**Note 6 – Other Non-Current Assets**

Other non-current assets consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Contingent consideration for retention related to sale of business | $15400 | $15150 |
| Indemnity holdback related to sale of business | 8801 | 8700 |
| Other | 89 | 167 |
|  | $24290 | $24017 |

---

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

**Note 7 – Other Non-Current Liabilities**

Other non-current liabilities consisted of the following:

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31, 2025** |
| Share-based payment liability-classified related to sale of business | $12983 | $15138 |
| Contingent consideration - Keystone acquisition | 1842 | 4625 |
| Other | 2297 | 2310 |
|  | $17122 | $22073 |

---

**Note 8 – Stock-Based Compensation**

***Stock Option Awards***

All of the outstanding stock option awards are fully vested. To date, there have been no stock option awards granted under the Strata Critical Medical, Inc. 2021 Omnibus Incentive Plan (f/k/a the Blade Air Mobility, Inc. 2021 Omnibus Incentive Plan) (the "Plan").

Following is a summary of stock option activities for the three months ended March 31, 2026:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Options** | **Weighted<br>Average<br>Exercise Price** | &nbsp;&nbsp;**Weighted**<br>**Average**<br>**Grant Date**<br>**Fair Value** | &nbsp;&nbsp;&nbsp;**Weighted**<br>**Average**<br>**Remaining**<br>**Life**<br>**(years)** | **Intrinsic**<br>**Value** |
| Outstanding – January 1, 2026 | 2896208 | $0.19 | $0.32 | 3.0 |  |
| &nbsp;&nbsp;Exercised | (286960) | 0.18 | 0.11 |  | $1370 |
| Outstanding – March 31, 2026 | 2609248 | $0.19 | $0.34 | 2.6 | $10418 |
| Exercisable as of March 31, 2026 | 2609248 | $0.19 | $0.34 | 2.6 | $10418 |

---

***Restricted Stock Units***

During the three months ended March 31, 2026, the Company granted 994,715 restricted stock units ("RSUs") to various employees, officers, directors, consultants, and vendors and 3,206,052 performance-based (tied to multi-year financial targets) restricted stock units ("PSUs") granted to named executive officers, key employees and vendors under the Plan (based on the target number of shares that may be issued assuming all performance targets are met), for an aggregate of 4,200,767.

The RSUs have various vesting dates, ranging from vesting on the grant date to as late as four years from the date of grant.

The PSUs granted in February 2026 have a three-year service period ending on December 31, 2028 and a grant-date fair value of $4.20 per share. These awards will vest based on the achievement of the specified Adjusted EBITDA targets and subject to continued service through the service period. Each PSU represents the right to receive one share of the Company's common stock.

Compensation expense associated with PSUs is recognized over the service period of the awards that are ultimately expected to vest when the related performance objective is met. The estimate of the number of awards expected to vest is reassessed each reporting period.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

Following is a summary of restricted stock unit activities for the three months ended March 31, 2026:

---

| | | |
|:---|:---|:---|
|  | **Restricted Stock Units** | **Weighted Average Grant Date**<br>**Fair Value** |
| Non-vested – January 1, 2026 | 9745980 | $3.84 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted - RSUs | 994715 | 4.22 |
| &nbsp;&nbsp;&nbsp;&nbsp;Granted - PSUs | 3206052 | 4.20 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vested | (336098) | 3.93 |
| &nbsp;&nbsp;&nbsp;&nbsp;Forfeited | (52755) | 3.20 |
| Non-vested – March 31, 2026 (1) | 13557894 | $3.95 |

---

(1) Includes 7,235,380 of PSUs that will vest subject to the achievement of Adjusted EBITDA and Free Cash Flow goals by the Company and 2,950,219 awards (RSUs and PSUs) held by the Company's former Chief Executive Officer that were modified in connection with the sale of the Passenger business. The modification changed the vesting conditions but did not affect the number of awards outstanding. See Note 4 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 for further information.

As of March 31, 2026, unamortized stock-based compensation costs related to restricted share arrangements (RSUs and PSUs) were $22,289 and will be recognized over a weighted average period of 2.1 years (with PSUs based on the full service period).

***Stock-Based Compensation Expense***

Stock-based compensation expense for stock options and restricted stock units in the unaudited interim condensed consolidated statements of operations is summarized as follows:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Selling, general and administrative expense | $5035 | $3809 |

---

**Note 9 – Segment and Geographic Information**

***Segment Information***

Operating segments are defined as components of an enterprise that engage in business activities for which discrete financial information is available that is evaluated regularly by the chief operating decision makers ("CODM") and is used in resource allocation and performance assessments.

The Company has identified two operating and reportable segments – Logistics and Clinical. Our co-Chief Executive Officers, who serve as the CODMs, regularly review discrete financial information for these two reportable segments. Gross profit is the measure of segment performance used by the CODMs. The CODMs consider budget-to-actual variances and year-over-year changes in Gross profit when making resource allocation decisions across our segments. Gross profit reflects the operational efficiency and core results of our segments, independent of tax implications and non-operational financial factors. Assets are managed on an entity-wide basis and are not allocated to or reviewed at the reportable segment level. Accordingly, the Company does not report asset information by segments.

The following table reflects certain financial data of the Company's reportable segments and includes the reconciliation to income (loss) from continuing operations before income taxes.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
| | **2026** | **2025** |
| Logistics: |  |  |
| &nbsp;&nbsp;Revenue | $47599 | $35948 |
| &nbsp;&nbsp;Cost of revenue | 38434 | 28895 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | $9165 | $7053 |
| Clinical: |  |  |
| &nbsp;&nbsp;Revenue | $19785 | $— |
| &nbsp;&nbsp;Cost of revenue | 14833 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | $4952 | $— |
| Consolidated: |  |  |
| &nbsp;&nbsp;Revenue | $67384 | $35948 |
| &nbsp;&nbsp;Cost of revenue | 53267 | 28895 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gross profit | $14117 | $7053 |
| Reconciliation: |  |  |
|  | **Three Months Ended<br>March 31,** | **Three Months Ended<br>March 31,** |
|  | **2026** | **2025** |
| Gross profit | $14117 | $7053 |
| &nbsp;&nbsp;Less: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 15605 | 12330 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of intangible assets | 1486 | 408 |
| &nbsp;&nbsp;Operating loss from continuing operations | (2974) | (5685) |
| &nbsp;&nbsp;Less: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income, net | 473 | 1321 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of warrant liabilities | 1459 | 2752 |
| &nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of assets and other liabilities | 3444 |  |
| &nbsp;&nbsp;Income (loss) from continuing operations before income taxes | $2402 | $(1612) |

---

---

| | | |
|:---|:---|:---|
| | **March 31, 2026** | **December 31,<br>2025** |
| **Goodwill** | | |
| &nbsp;&nbsp;Logistics | $15540 | $15540 |
| &nbsp;&nbsp;Clinical | 73049 | 72670 |
| Total Goodwill | $88589 | $88210 |

---

**Note 10 – Income Taxes** 

The Company's effective tax rate represents the Company's estimated tax rate for the year based on projected income, adjusted for any discrete transactions occurring during the period. Discrete transactions during the three months ended March 31, 2026 related to changes in the fair value of contingent consideration associated with the sale of the Passenger business and the acquisition of Keystone as well as other subsequent tax effects of those transactions. Tax effects of discrete transactions were attributable to discontinued operations.

For the three months ended March 31, 2026 and 2025, no income tax expense (benefit) was recognized through continuing operations. The Company maintains a full valuation allowance on net deferred tax assets as of March 31, 2026 and December 31, 2025, primarily due to uncertainties of the future utilization of deferred tax assets relating primarily to net operating loss carryforwards for US federal and state income tax purposes.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

The Company's net deferred tax liability is what is commonly referred to as a "naked credit" or "hanging credit". A naked credit exists when a Company is subject to a valuation allowance and maintains a deferred tax liability that cannot be considered as a source of future taxable income for valuation allowance purposes, either because its reversal is indefinite in nature or otherwise. The result of a naked credit is a deferred tax liability that remains on the balance sheet.

**Note 11 – Earnings per Common Share**

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Diluted earnings (loss) per common share is calculated using the more dilutive of the treasury stock method or the two-class method. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised and is computed after giving consideration to the weighted average dilutive effect of the Company's stock options, warrants, and non vested restricted stock, where applicable. Antidilutive securities are disregarded in earnings per share calculations. For the periods in which the Company reports a net loss, all potentially dilutive securities are excluded from the computation of diluted loss per share as their inclusion would be anti-dilutive.

A reconciliation of net income (loss) and common share amounts used in the computation of basic and diluted income (loss) per common share is presented below.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| **Numerator:** |  |  |
| Net income (loss) from continuing operations | $2402 | $(1612) |
| Net loss from discontinued operations | (248) | (1881) |
| &nbsp;&nbsp;Net income (loss) | $2154 | $(3493) |
| **Denominator:** |  |  |
| Weighted-average number of common shares (basic) | 85322941 | 79891829 |
| Effect of dilutive securities: |  |  |
| &nbsp;&nbsp;Options to purchase shares of common stock | 2507734 |  |
| &nbsp;&nbsp;Restricted shares of common stock | 2338178 |  |
| Total effect of dilutive securities | 4845912 |  |
| Weighted-average number of common shares (diluted) | 90168853 | 79891829 |
| **Basic earnings (loss) per share** |  |  |
| &nbsp;&nbsp;Continuing operations | $0.03 | $(0.02) |
| &nbsp;&nbsp;Discontinued operations |  | (0.02) |
| Total basic earnings (loss) per share | $0.03 | $(0.04) |
| **Diluted earnings (loss) per share** |  |  |
| &nbsp;&nbsp;Continuing operations | $0.03 | $(0.02) |
| &nbsp;&nbsp;Discontinued operations |  | (0.02) |
| Total diluted earnings (loss) per share | $0.03 | $(0.04) |

---

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three months ended March 31, 2026. For the three months ended March 31, 2025, all potentially dilutive securities shown below were excluded from the computation of diluted loss per share as the Company was in a net loss position and their inclusion would have been anti-dilutive.

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
| Warrants to purchase shares of common stock (1) | 14166644 | 14166644 |
| Options to purchase shares of common stock |  | 3556349 |
| Outstanding shares in escrow (2) | 1041969 |  |
| Restricted shares of common stock (3) | 8869832 | 10879863 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total potentially dilutive securities | 24078445 | 28602856 |

---

(1) Warrants are excluded because the effect of their inclusion would be anti-dilutive as their exercise price exceeds the average market price of the Company's common stock.

(2) 1,041,969 shares remaining in escrow to cover potential indemnification obligations for breaches of general representations and warranties under the Keystone Purchase Agreement. These shares are legally issued and outstanding but are excluded from the weighted average shares outstanding calculation as they are contingently returnable pending expiration of the representations and warranties survival period in September 2026.

(3) Contingently issuable pending satisfaction of the applicable vesting and performance conditions, consisting of 5,918,814 shares related to officer, employee and vendor PSUs and 2,950,219 shares related to Earn-out PSUs and time-based awards granted to the Company's former Chief Executive Officer. 799 shares excluded as their inclusion would be anti-dilutive under the treasury stock method.

**Note 12 – Commitments and Contingencies**

***Capacity Purchase Agreements***

The Company has contractual relationships with various aircraft operators to provide aircraft service. Under these capacity purchase agreements ("CPAs"), the Company pays the operator contractually agreed fees (carrier costs) for operating these flights. The fees are generally based on fixed hourly rates for flight time multiplied by hours flown. Under these CPAs, the Company is also responsible for landing fees and other costs, which are either passed through by the operator to the Company without any markup or directly incurred by the Company.

As of March 31, 2026, the Company has total remaining unfulfilled obligations of $2,304 for the year ending December 31, 2026. The remaining unfulfilled obligation includes amounts within operating lease liability related to aircraft leases embedded within our capacity purchase agreements as included in the operating right-of-use asset and lease liability.

***Legal and Environmental***

From time to time, we may be a party to litigation that arises in the ordinary course of business. We do not have any pending litigation that, separately or in the aggregate, would, in the opinion of management, have a material adverse effect on its results of operations, financial condition or cash flows. As of March 31, 2026, management believes, after considering a number of factors, including (but not limited to) the information currently available, the views of legal counsel, the nature of contingencies to which the Company is subject and prior experience, that the ultimate disposition of these other litigation and claims will not materially affect the Company's consolidated financial position or results of operations. The Company records liabilities for legal and environmental claims when a loss is probable and reasonably estimable. These amounts are recorded based on the Company's assessments of the likelihood of their eventual disposition. The Company's view and estimates related to these matters may change in the future, as new events and circumstances arise and as the matters continue to develop.

**Note 13 – Warrant Liabilities**

On May 7, 2021, the merger between Blade Urban Air Mobility, Inc. and the Company (then a special purpose acquisition company known as Experience Investment Corp. ("EIC") was consummated (the "Merger"). The warrants acquired in the Merger include (a) redeemable warrants issued by EIC and sold as part of the units in the EIC Initial Public Offering ("EIC

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

IPO") (whether they were purchased in the EIC IPO or thereafter in the open market), which are exercisable for an aggregate of 9,166,644 shares of common stock at a purchase price of $11.50 per share (the "Public Warrants") and (b) warrants issued by EIC to Sponsor in a private placement simultaneously with the closing of the EIC IPO, which are exercisable for an aggregate of 5,000,000 shares of common stock at a purchase price of $11.50 per share (the "Private Placement Warrants").

The Company evaluated its warrants under ASC 815-40, *Derivatives and Hedging—Contracts in Entity's Own Equity*, and concluded that they do not meet the criteria to be classified in stockholders' equity. Accordingly, the Company classifies the warrants as liabilities at their fair value and adjusts the warrants to fair value at each reporting period. This liability is subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company's unaudited interim condensed consolidated statements of operations. See Note 14 – Fair Value Measurements for additional information.

***Warrants*** — Public Warrants may only be exercised for a whole number of shares. The Public Warrants became exercisable on June 7, 2021. The Public Warrants will expire on May 7, 2026 or earlier upon redemption or liquidation.

*Redemptions of Warrants for Cash* — The Company may redeem the Public Warrants:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in whole and not in part;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• at a price of $0.01 per warrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• upon not less than 30 days' prior written notice of redemption to each warrant holder; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if, and only if, the reported last sale price of the Company's common stock equals or exceeds $18.00 per share for any 20 trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to each warrant holder.

*Redemption of Warrants for Shares of Common Stock* — The Company may redeem the outstanding warrants:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• in whole and not in part;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• at a price equal to a number of shares of common stock to be determined, based on the redemption date and the fair market value of the Company's common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• upon a minimum of 30 days' prior written notice of redemption;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if, and only if, the last reported sale price of the Company's common stock equals or exceeds $10.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations, and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• if, and only if, there is an effective registration statement covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating thereto is available throughout the 30-day period after the written notice of redemption is given.

If the Company calls the Public Warrants for redemption for cash, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a "cashless basis", as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, recapitalization, reorganization, merger, or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price below its exercise price. Additionally, in no event will the Company be required to net-cash settle the warrants.

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the initial public offering, except that the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees (unless the Company's common stock equals or exceed $10 per share and the Company redeems all the Public Warrants). If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

**Note 14 – Fair Value Measurements**

The following table presents information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2026 and December 31, 2025, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value.

---

| | | | |
|:---|:---|:---|:---|
| | **Level** | **March 31, 2026** | **December 31, 2025** |
| **Assets** | | | |
| Money market fund (1) | 1 | $51787 | $23111 |
| Contingent consideration asset related to sale of business (2) | 3 | 28820 | 27700 |
| Indemnity holdback related to sale of business (2) | 3 | 8801 | 8700 |
| &nbsp;&nbsp;&nbsp;Total assets at fair value |  | $89408 | $59511 |
| **Liabilities** |  |  |  |
| Warrant liabilities - Public Warrants | 1 | $46 | $990 |
| Warrant liabilities - Private Warrants | 2 | 25 | 540 |
| Share-based payment liability-classified related to sale of business (3) | 3 | 12983 | 15138 |
| Equity consideration in escrow and contingent consideration - Keystone acquisition (4) | 3 | 9004 | 9072 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities at fair value |  | $22058 | $25740 |

---

(1) As of March 31, 2026 and 2025, the Company had cash equivalents held in a money market fund. The Company has concluded that due to the highly liquid nature of the fund, the carrying value approximates fair value, which represents a Level 1 input. The balance of cash equivalents held in the money market fund is included in cash and cash equivalents.

(2) Contingent consideration and indemnity holdback related to sale of the Passenger business are presented within "Prepaid expenses and other current assets" and "Other non-current asset", respectively, on the unaudited interim condensed consolidated balance sheets.

(3) Share-based payment liability-classified related to the sale of the Passenger business is presented within "Other non-current liabilities" on the unaudited interim condensed consolidated balance sheets.

(4) Equity consideration in escrow and contingent consideration related to the Keystone acquisition are presented under "Accounts payable and accrued expenses" and "Other non-current liabilities" as applicable.

There were no transfers between levels of the fair value hierarchy during the three months ended March 31, 2026.

***Fair Value of Warrant Liabilities***

The Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within "Warrant liability" on the Company's unaudited interim condensed consolidated balance sheets. The warrant liabilities are measured at fair value upon initial recognition and on a recurring basis, with changes in fair value presented within "Change in fair value of warrant liabilities" in the unaudited interim condensed consolidated statements of operations.

The Public Warrants are considered part of Level 1 of the fair value hierarchy, as those securities are traded on an active public market. At May 7, 2021 and thereafter, the Company valued the Private Warrants using Level 2 of the fair value hierarchy. The Company used the value of the Public Warrants as an approximation of the value of the Private Warrants as they are substantially similar to the Public Warrants, but not directly traded or quoted on an active market.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

***Subsequent Measurement - Warrant Liabilities***

The following table presents the changes in fair value of the warrant liabilities:

---

| | | | |
|:---|:---|:---|:---|
| | **Public**<br>**Warrants** | &nbsp;&nbsp;&nbsp;**Private** <br>**Placement**<br>**Warrants** | **Total Warrant**<br>**Liability** |
| Fair value as of January 1, 2026 | $990 | $540 | $1530 |
| Change in fair value of warrant liabilities | (944) | (515) | (1459) |
| Fair value as of March 31, 2026 | $46 | $25 | $71 |

---

***Subsequent Measurement - Level 3 Assets and Liabilities***

The following table presents the changes in fair value of the Level 3 assets for the three months ended March 31, 2026:

---

| | | | |
|:---|:---|:---|:---|
| | **Contingent Consideration asset** | &nbsp;&nbsp;&nbsp;**Indemnity Holdback** | **Total** |
| Fair value as of January 1, 2026 | $27700 | $8700 | $36400 |
| Change in fair value | 1120 | 101 | 1221 |
| Fair value as of March 31, 2026 | $28820 | $8801 | $37621 |

---

The following table presents the changes in fair value of the Level 3 liabilities for the three months ended March 31, 2026:

---

| | | | |
|:---|:---|:---|:---|
| | **Share-Based Payment Liability** | &nbsp;&nbsp;&nbsp;**Equity Consideration in Escrow and Contingent Consideration - Keystone** | **Total** |
| Fair value as of January 1, 2026 | $15138 | $9072 | $24210 |
| Change in fair value | (2155) | (68) | (2223) |
| Fair value as of March 31, 2026 | $12983 | $9004 | $21987 |

---

**Note 15 – Stockholders' Equity**

***Preferred Stock***

The Board of Directors of the Company (the "Board") is authorized to provide, out of the unissued shares of Preferred Stock, for one or more series of Preferred Stock and, with respect to each such series, to fix, without further stockholder approval, the number of shares constituting such series and the designation of such series, the powers (including voting powers), preferences and relative, participating, optional and other special rights, and the qualifications, limitations or restrictions thereof, of such series of Preferred Stock. The powers (including voting powers), preferences and relative, participating, optional and other special rights of, and the qualifications, limitations or restrictions thereof, of each series of Preferred Stock, if any, may differ from those of any and all other series at any time outstanding. There was no preferred stock issued and outstanding as of March 31, 2026 or 2025.

**Note 16 – Credit Facility**

***Description of the ABL Facility***

On January 30, 2026, the Company entered into a secured asset-based revolving credit facility (the "ABL Facility") pursuant to a Credit Agreement (the "Credit Agreement") among the Company, certain of its subsidiaries as guarantors, and JPMorgan Chase Bank, N.A., as administrative agent. The ABL Facility provides for revolving borrowings of up to $30.0 million, subject to customary borrowing base limitations based on eligible accounts receivable, and includes an accordion feature permitting increases of up to an additional $20.0 million, subject to lender consent and other customary

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**STRATA CRITICAL MEDICAL, INC.**

**Notes to Unaudited Interim Condensed Consolidated Financial Statements**

*(amounts in thousands, except share and per share data)*

conditions. The ABL Facility matures on January 30, 2029 and is available for working capital and general corporate purposes.

***Interest Rate and Fees***

Borrowings under the ABL Facility bear interest, at the Company's election, at either (i) an adjusted term Secured Overnight Financing Rate ("SOFR") plus an applicable margin of 2.00%, or (ii) a floating SOFR-based rate plus an applicable margin of 2.00%. The Company is also required to pay a commitment fee of 0.25% per annum on the daily average unused portion of the ABL Facility. As of March 31, 2026, no amounts were outstanding under the ABL Facility.

***Security and Guarantees***

The obligations under the ABL Facility are guaranteed by certain subsidiaries of the Company and are secured by a first-priority lien on substantially all eligible personal property of the loan parties, excluding owned aircraft.

***Restrictive Covenants***

The Credit Agreement contains customary affirmative and negative covenants that, among other things, limit the Company's and its subsidiaries' ability to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• incur additional indebtedness or guarantee obligations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• create or permit liens on assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• undertake certain mergers, consolidations, or other fundamental changes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• make certain investments, acquisitions, or capital expenditures beyond specified thresholds;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enter into asset sales or sale-leaseback transactions outside the ordinary course of business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• pay dividends on, or repurchase, common stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• make certain debt prepayments or restricted payments; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• enter into transactions with affiliates on non-arm's-length terms.

The Credit Agreement also includes customary events of default, including payment defaults, covenant breaches, cross-defaults to material indebtedness, and certain insolvency events. Upon an event of default, the lenders may, among other remedies, terminate commitments, accelerate outstanding obligations, and exercise remedies against the collateral. As of March 31, 2026, the Company was in compliance with all covenants under the Credit Agreement.

***Debt Issuance Costs***

The Company incurred debt issuance deferred costs of $0.3 million during the three months ended March 31, 2026. The deferred costs are being amortized on a straight-line basis over the 36-month term of the ABL Facility.

**Note 17 – Subsequent Events**

On April 30, 2026, Keystone acquired substantially all of the assets of Ohio Valley Perfusion Associates, Inc., a regional provider of perfusion services to cardiac surgery programs in Ohio and Pennsylvania, for aggregate cash consideration of approximately $1.0 million.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**Item 2. Management's discussion and analysis of financial condition and results of operations**

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2025.* 

*In addition to historical consolidated financial information, the following discussion contains forward-looking statements that reflect our plans, estimates, and beliefs.*

**Forward-Looking Statements**

This Quarterly Report on Form 10-Q may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements can generally be identified using forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "seeks", "projects", "intends", "plans", "may", "will" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include all matters that are not historical facts. They appear in several places throughout this report and include statements regarding our intentions, beliefs or current expectations concerning, among other things, results of operations, financial condition, liquidity, prospects, growth, strategies and the markets in which we operate. Such forward-looking statements are based on available current market material and management's expectations, beliefs, and forecasts concerning future events impacting us and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.

Our operations and financial results are subject to various risks and uncertainties. The following are among those factors, but are not the only factors, that could adversely affect us and/or that may cause actual results to differ materially from such forward-looking statements:

<u>Risks Related to Our Business and Growth Strategy</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• continued net losses or failure to achieve or maintain profitability;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to realize the anticipated benefits of strategic transactions, including the recently completed divestiture of the Passenger business, the acquisition and integration of Keystone (as defined below), and any future acquisitions or partnerships;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• harm to our reputation or brand arising from operational issues, public perception, clinical outcomes or actions of third parties;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• negative publicity, litigation, claims or regulatory scrutiny relating to our clinical services, perfusion staffing or organ recovery activities;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to provide high-quality customer support and maintain trusted relationships with Medical Customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on contractual relationships with transplant centers, hospitals, Organ Procurement Organizations and strategic partners;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• adoption and effective utilization of our integrated clinical and logistics offerings by Medical Customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• competition within the transplant logistics, clinical services and organ preservation ecosystem;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our dependence on the availability and utilization of donor organs and transplant volumes;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• insufficient reimbursement or funding for organ transport and related services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks inherent in organ transportation operations, including delivery failures, operational disruptions or liability exposure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with ground transportation operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• advancements in preservation technology or alternative transport methods that could reduce demand for our services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• aviation safety risks, including accidents, incidents or adverse publicity involving aircraft used in our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• climate change, extreme weather events or environmental developments affecting our operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• terrorist attacks, geopolitical conflict or security events affecting aviation or healthcare infrastructure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• volatility in aircraft fuel availability or cost;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to obtain additional capital or financing;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• restrictions under our Credit Agreement that may limit operational or strategic flexibility;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to manage growth, operational expansion and integration activities effectively;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• insurance market conditions, including increased premiums, reduced coverage availability or changes in underwriting standards;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our dependence on key personnel and our ability to attract and retain qualified professionals;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• employment-related claims, workforce litigation or labor market challenges;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain our company culture as we grow;

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• fluctuations in financial results and the non-comparability of historical financial statements following discontinued operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with purchasing aircraft or evolving from an asset-light model;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with directly operating aircraft, including increased regulatory oversight, operational complexity or liability exposure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on maintaining efficient aircraft utilization to manage costs, operating efficiency and margins;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• changes in regulatory frameworks; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• comparability of historical financial results due to the effects of discontinued operations for the Passenger business.

<u>Risks Related to Our Dependence on Third-Party Providers</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on third-party aircraft operators to provide and operate aircraft used in our services;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the availability of sufficient third-party aircraft capacity and our ability to add or retain operators to meet demand;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• workforce disruptions, operational interruptions or financial difficulties affecting third-party operators or service providers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• reputational or operational risks arising from the illegal, improper or otherwise inappropriate operation of Strata-owned or Strata-branded aircraft by third-party operators; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our reliance on third-party cloud infrastructure, hosting providers and other technology vendors to support our systems and operations.

<u>Risks Related to Intellectual Property, Cybersecurity, Information Technology and Data Management Practices</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• interruptions, defects, failures or vulnerabilities in our technology systems or those of third-party providers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• cybersecurity incidents, data breaches or misuse of artificial intelligence technologies that could disrupt operations or expose sensitive information;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to protect and enforce intellectual property rights; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• risks associated with our use of open-source software.

<u>Legal and Regulatory Risks Related to Our Business</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our operations within highly regulated aviation, healthcare and transplant environments, including evolving federal, state and local laws and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the impact of any litigation or regulatory investigations that we may be subject to;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to comply with privacy, data protection, consumer protection and security laws; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the expansion of environmental regulations.

<u>Other Risks</u> 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to remediate any material weaknesses or maintain effective internal controls over financial reporting;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• our ability to maintain effective disclosure controls and procedures; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the other factors described elsewhere in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2025, included under the headings "Risk Factors," "Management's Discussion and Analysis of Financial Condition" or as described in the other documents and reports we file with the SEC.

Actual results, performance or achievements may differ materially, and potentially adversely, from any forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance. All information set forth herein speaks only as of the date hereof and we disclaim any intention or obligation to update any forward-looking statements, whether as a result of new information, changes in expectations, future events or otherwise.

**Overview** 

Strata Critical Medical, Inc. (f/k/a Blade Air Mobility, Inc.) ("Strata" or the "Company") is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates one of the nation's largest air transport and surgical services networks for transplant hospitals and Organ Procurement Organizations ("OPOs"), offering an integrated "one call" solution for donor organ recovery. Strata's core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion and preservation for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions ("Trinity") and Keystone brands.

Strata's mission is to increase the number of organs that are successfully transplanted while leveraging the Company's expertise and resources to provide other medical and logistics services to a broader customer base. Strata's goals are

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

closely aligned with those of all participants in the transplant ecosystem, including transplant centers, regulators, OPOs, and other service providers. We believe that, by working with Strata, industry participants can save money, save more lives and operate more efficiently.

Beginning with the fourth quarter of 2025, following the integration of Keystone, Strata operates across two segments: Logistics and Clinical, both offering services related to organ transplant and the broader healthcare industry. All of Strata's services are provided to transplant centers, OPOs, hospitals, or other businesses that pay the Company directly.

<u>Logistics Segment</u>

Strata's Logistics segment is marketed under the Trinity brand name and includes the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Air Logistics – Air transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Service is typically provided on fixed wing aircraft operating specifically for each individual organ. Strata also offers on-board couriers for commercial flights and "next flight out" shipping coordination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ground Logistics – Ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organ Placement – Administrative services related to the acceptance of potential donor organs for recipients and support coordinating with the transplant process.

<u>Clinical Segment</u>

Strata's Clinical segment is marketed under the Keystone brand name and includes the following:

Transplant Clinical

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Organ Recovery – Surgical procurement of donor organs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Normothermic Regional Perfusion ("NRP") – In situ perfusion of donor organs with oxygenated blood to improve clinical outcomes and enable functional assessment prior to recovery.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Preservation – Operation of devices utilized to preserve organs prior to being transplanted into a recipient.

Other Clinical Services

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cardiac Care – Cardiac perfusion, blood management & autotransfusion and disposables. Services are typically provided under contract with hospitals to support open-heart surgery procedures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Other – Extracorporeal Membrane Oxygenation ("ECMO") services, perfusion temporary staffing and equipment rental offered to healthcare providers.

*Sale of Passenger Business* 

On August 29, 2025, the Company completed the previously disclosed sale of its Passenger business to Joby Aero, Inc. ("Joby Buyer"), pursuant to an Equity Purchase Agreement, dated August 1, 2025 (the "Joby Purchase Agreement"). The Passenger business acquired by Joby Buyer consisted of the Company's business of offering, selling, promoting, marketing, planning, booking, brokering, coordinating and arranging the transportation of passengers on aircraft operated by other entities and related ground transportation services. The purchase price received by the Company upon the consummation of the transactions contemplated by the Joby Purchase Agreement was approximately $76.0 million based on the closing price per share of $14.27 of Joby Aviation Inc's ("Joby Aviation") common stock as of August 28, 2025, after giving effect to certain pre-closing adjustments and indemnity holdbacks pursuant to the terms of the Joby Purchase Agreement, consisting of 5,325,585 shares of Joby Aviation's common stock, par value $0.0001 per share (the "Buyer Shares"). The Company subsequently sold the Buyer Shares received in connection with closing for net proceeds of $70.2 million. The Company may receive up to an additional $35.0 million in consideration upon the satisfaction of certain financial performance and employee retention targets described in the Joby Purchase Agreement during the 12 and 18 months, respectively, following the closing of this transaction, payable in cash or Buyer Shares at Joby Buyer's election, as well as the release of up to $10.0 million in indemnity holdbacks. The number of Buyer Shares issued to the Company, if any, shall be based on the average of the daily volume-weighted average sales price per Buyer Share on the New York Stock Exchange for each of the ten consecutive trading days ending on and including the first trading day preceding the applicable measurement dates described in the Joby Purchase Agreement.

The sale qualified as a discontinued operation under ASC 205-20. The Passenger business acquired by Joby Buyer included all operations previously reported within the Passenger segment, as well as certain assets and activities previously

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

reported within unallocated corporate expenses and software development, including certain costs related to software development personnel, the Company's former CEO and headquarter lease.

The results of operations through August 29, 2025, the transaction date, reflect the financial results of the Passenger business as discontinued operations. The cash flows and comprehensive income of the Passenger business have not been separately presented and are included in the unaudited interim condensed consolidated statements of cash flows and unaudited interim condensed consolidated statements of comprehensive loss, respectively, for the prior year period. Unless otherwise indicated, the information in the notes to the consolidated financial statements refer only to Strata's continuing operations and do not include discussion of balances or activity of the Passenger business.

*Acquisition of Keystone Perfusion Services, LLC*

On September 16, 2025, the Company completed the acquisition of Keystone Perfusion Services, LLC ("Keystone"), an organ recovery and normothermic regional perfusion service provider to the transplant industry, pursuant to a Purchase and Sale Agreement, dated September 16, 2025 (the "Keystone Purchase Agreement"), for the following upfront payments: cash $111.3 million (comprised of $67.0 million paid directly to the seller and $44.3 million directed by the seller to other parties on the close date) and 3,434,609 shares of the Company's common stock (where 1,717,303 were held in escrow at closing). The purchase consideration was subject to adjustment based on Keystone's actual 2025 Adjusted EBITDA performance. Based on that performance, 675,334 shares were returned from escrow and retired during the three months ended March 31, 2026, reducing the shares remaining in escrow to 1,041,969, the remainder of which is held to cover potential indemnification obligations under the Keystone Purchase Agreement. In addition, total potential earn-out payments of up to $23.0 million in the aggregate for the three-year period from 2026 through 2028 may be made contingent upon Keystone's achievement of gross profit targets (as defined in the Keystone Purchase Agreement).

**Our Business Model**

*Logistics Services*

We typically provide logistics services to transplant centers, OPOs, and other businesses on a contractual basis including provisions stipulating that Strata will be the "first call" for any transportation needs.

Pricing is based on a fixed price per flight hour flown with a fuel cost surcharge above a set benchmark. Ancillary costs such as landing fees and de-icing are passed through to the end customer.

Strata leverages an asset-light air logistics business model: we primarily utilize aircraft that are owned and/or operated by third parties on Strata's behalf. In these arrangements, pilots, maintenance, hangar, insurance, and fuel are all costs borne by our network of operators, which provide aircraft flight time to Strata at fixed hourly rates. This enables our operator partners to focus on training pilots, maintaining aircraft, and flying, while we maintain the relationship with our customer from booking through flight arrival.

When utilizing third-party aircraft and/or aircraft operators, we typically pre-negotiate fixed hourly rates and flight times, paying only for flights actually flown, creating a predictable and flexible cost structure. Strata provides guaranteed flight commitments to some of our third-party operators through capacity purchase agreements ("CPAs"), which enable Strata to ensure dedicated access to such aircraft with enhanced crew availability, lower costs and, in many cases, the ability to unlock more favorable rates when flying more than the minimum number of hours we guarantee to the operator. Additionally, a significant portion of trips are flown by safety-vetted operators to whom we make no commitments, providing us with additional flexible capacity for high demand periods.

We own ten fixed wing aircraft that are dedicated to the Logistics segment. We have invested in a limited number of owned aircraft based in high-volume geographies as we believe direct asset ownership will enable (i) improved economies of scale; (ii) increased uptime, enabling more reliable service and higher asset utilization; and (iii) the ability to compete for certain contracts where asset ownership is preferred or required. All of these aircraft are operated and maintained by third-party service providers under Strata's oversight. We prioritize the use of owned aircraft and dedicated aircraft under CPAs, which provide better economies of scale. We size our owned fleet and our commitments under CPAs significantly below our expected demand, enabling us to maximize utilization on those aircraft while fulfilling incremental demand through our network of non-dedicated operators.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

We provide ground logistics using a combination of owned vehicles, which are allocated to hubs positioned near our customers across the United States, and third-party providers.

We utilize a combination of Company employees and contractors as couriers to facilitate the transportation of organs, typically kidneys, aboard scheduled commercial flights. For next flight out ("NFO") services, where kidneys are placed in the cargo hold of a commercial flight, we coordinate with third-party providers on behalf of our customer.

Organ placement services are provided on a contractual basis with a fixed monthly fee based on the size of the customer's program.

*Clinical Services*

We employ perfusionists and transplant surgeons that are primarily dedicated to a specific customer in a particular geography. We own perfusion equipment which is often provided as part of our services or offered through a traditional leasing arrangement.

Our clinical work for OPOs typically consists of surgical recovery, NRP services, and related equipment provided on a contractual basis with a combination of retainer and per case fees.

For transplant centers, surgical recovery and NRP services are typically provided on an ad hoc basis with pricing on a per case basis. We leverage surgeons, perfusionists, and equipment in place to support our OPO customers to provide more efficient options to transplant centers, utilizing locally available resources wherever possible to avoid incremental logistics costs.

For cardiac care hospitals, we typically provide perfusion staffing, often combined with perfusion equipment, on a contractual basis with a combination of retainer and per case fees.

*Technology*

We also utilize proprietary technology to manage staffing, training, and chain of custody, as well as help customers streamline organ evaluation, procurement, and logistics. Our technology enhances the efficiency and cost-effectiveness of our service offerings, further strengthening our position in the organ transportation industry.

**Factors Affecting our Performance** 

***Availability of Donor Organs***

The majority of our business is directly tied to the volume of heart, liver, and lung transplants performed in the United States, which is driven primarily by the supply of donor organs that become available.

In recent years, the supply of donor organs has increased consistently, driven primarily by (i) increased utilization of Donation after Circulatory Death, which has expanded the pool of eligible donors; (ii) advancements in technology, including machine and regional perfusion; and (iii) regulatory changes enabling more efficient allocation of organs to recipients with higher need. However, there is no guarantee that this growth will continue, for example, recent months have shown a flattening in the number of deceased organ donors in America.

The supply of donor organs is subject to numerous factors outside our control, including changes in organ donation rates, advancements in medical technology, legislative, regulatory or policy changes affecting organ procurement and allocation, and shifts in public attitudes toward organ donation. Additionally, unforeseen events such as pandemics, public health crises, or changes in accident rates may impact the availability of donor organs. If the supply of viable organs declines or if legislative, regulatory or policy changes limit our ability to efficiently transport them, our medical transport business could be adversely affected, which could negatively impact our financial condition and growth prospects.

***Ability to Attract and Retain Customers***

We primarily serve transplant centers, OPOs, and hospitals. Logistics support for the hearts, lungs, and livers transplantations that make up the vast majority of our business is typically requested only hours before the required departure time. Our ability to successfully fulfill these requests with consistent pricing on the requested aircraft type is the primary metric by which our customers evaluate our logistics performance.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

The organ logistics marketplace is highly competitive and we compete primarily on our ability to provide reliable, end-to-end air and ground transportation at competitive pricing. Increasingly, we compete directly with manufacturers of organ preservation equipment that also offer transportation or with providers that offer additional services, such as surgical organ recovery, that our customers find valuable.

We have responded to customer demand by introducing new services through our acquisition of Keystone, which launched our Clinical segment and enabled us to provide surgical recovery, NRP, and other related services as part of an end-to-end offering. We have also added new offerings organically, such as our TOPS organ placement offering, whereby we assist customers in evaluating the suitability of potential donor organs for transplant. However, customers may still demand services or technology that we cannot provide, which could have a material adverse effect on our business, results of operations, and financial condition.

The market for our clinical service offerings, including surgical organ recovery, organ placement, and perfusion, both for transplant and for cardiac care hospitals, is also highly competitive. We compete in our Clinical segment primarily on our ability to provide high-quality, reliable service integrating electronic recordkeeping to demonstrate compliance with best practices.

Specifically for our transplant-related services, we also compete on our ability to integrate offerings from our Logistics and Clinical segments, resulting in more streamlined communication and efficient transportation, saving time and money for our customers. Some of our competitors offer many of the same services we provide in an integrated "one call" offering, but we believe that our offering is more comprehensive in terms of both the variety of services we provide and the breadth of third-party devices that we support.

***Ability to Secure Aircraft Capacity***

Historically, our ability to aggregate significant demand for flights has been enough to incentivize operators to provide aircraft and crews for our use. However, there is no guarantee that we will continue to be able to secure dedicated aircraft at favorable rates, particularly given significant increases in demand for private jet aircraft in the United States in recent years. Periods of increased demand for private jets have historically led to increased charter costs and more limited availability in the spot jet charter market. Although this has not limited our ability to maintain or increase our access to dedicated jet aircraft at fixed prices in recent periods, there is no guarantee this will continue in the future.

To manage this risk, we enter into long-term capacity purchase agreements with aircraft owners and operators and have purchased a number of jet aircraft, all of which are 100% dedicated to Strata's needs.

***Ability to Hire, Train, and Retain Clinicians***

Our surgical recovery, NRP, organ placement, and cardiac care offerings depend on our ability to hire, train, and retain clinicians, particularly perfusionists and organ recovery surgeons.

Historically, our ability to aggregate demand across transplant centers and cardiac care hospitals has made us an attractive employer for clinicians and enabled us to optimize our staffing model to offer both competitive pricing to customers and attractive pay to our employees. However, given the significant growth in these fields as well as increasing competition, there is no guarantee this will continue.

***Impact of Inflation to our Business***

We generally pay a fixed hourly rate to our third-party operators based on flight hours flown. These rates are susceptible to inflation and are typically renegotiated on a yearly basis, though some multi-year contracts have fixed rate increases. Some contracts with operators allow for pass-through of fuel price increases above a set threshold. For our owned aircraft, we are more directly exposed to inflation of aircraft operating expenses, including pilot salaries, fuel, insurance, parts, and maintenance.

Given significant growth in organ transplant volumes and an increasing percentage of organs that are recovered by commercial surgeons and undergo NRP, demand for clinicians skilled in these procedures is high resulting in inflation in salaries and fees paid to these practitioners.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

We have historically passed through cost inflation to customers and most logistics contracts with customers automatically pass through any fuel surcharges, but there is no guarantee this will continue in the future.

***Seasonality*** 

Our Logistics trip volumes and Clinical case volumes are correlated with the overall supply of donor hearts, livers, and lungs in the United States, which can be volatile due to a variety of factors. Over the last several years, industry transplant volumes exhibited modest seasonal softness in the calendar third quarter, though our own case and flight volumes have not always followed this industry trend.

**Key Components of the Company's Results of Operations**

***Revenue***

Services are typically purchased through our coordinators and are paid for principally via checks and wires. Logistics services are typically provided and billed on a fee-for-service basis, while Clinical services are provided and billed on both a fee-for-service and retainer basis. Payments are generally collected after the performance of the related service in accordance with the client's payment terms. Fee-for-service revenue is recognized when the service is completed, while retainer revenue is recognized over the retainer contractual term.

***Cost of Revenue***

Cost of revenue consists of costs of operating our aircraft fleet, including pilots' salaries, flight costs paid to operators of aircraft and vehicles, depreciation of aircraft, vehicles and medical devices, staff costs directly supporting Logistics and Clinical services, and costs of disposable medical products.

***Selling, General and Administrative***

Selling, general and administrative ("SG&A") expenses consist primarily of: staff costs for employees in the commercial, technology, executive, marketing and administrative functions; sales commissions; stock-based compensation; professional and consulting fees; insurance; facilities; information technology and software development costs; promotional expenses; pilot training costs; impairment of assets; and other general corporate overhead costs. SG&A expenses are expensed as incurred.

***Amortization of Intangible Assets***

Amortization of intangible assets consists of amortization of customer lists, trademarks, technology acquired in business combinations and capitalized software development costs. Amortization expense is recognized on a straight-line basis over their estimated useful lives.

**Discontinued Operations**

On August 29, 2025, we completed the sale of our Passenger business to Joby Buyer pursuant to the Joby Purchase Agreement. We determined that the sale of the Passenger business represented a strategic shift that will have a major effect on our operations and financial results. Accordingly, the sale was classified as discontinued operations.

The results of operations for the three months ended March 31, 2025 reflect the financial results of the Passenger business as discontinued operations. There were no assets or liabilities of the Passenger business remaining as of March 31, 2026 or December 31, 2025. See Note 4 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**Results of Operations**

The following table presents our unaudited interim condensed consolidated statements of operations for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Revenue | $67384 | $35948 |
| &nbsp;&nbsp;Cost of revenue | 53267 | 28895 |
| Gross profit | 14117 | 7053 |
| Operating expenses |  |  |
| &nbsp;&nbsp;Selling, general and administrative | 15605 | 12330 |
| &nbsp;&nbsp;Amortization of intangible assets | 1486 | 408 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 17091 | 12738 |
| Operating loss from continuing operations | (2974) | (5685) |
| Other non-operating income |  |  |
| &nbsp;&nbsp;Interest income, net | 473 | 1321 |
| &nbsp;&nbsp;Change in fair value of warrant liabilities | 1459 | 2752 |
| &nbsp;&nbsp;Change in fair value of assets and other liabilities | 3444 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other non-operating income | 5376 | 4073 |
| Income (loss) from continuing operations before income taxes | 2402 | (1612) |
| &nbsp;&nbsp;Income tax expense from continuing operations |  |  |
| Net income (loss) from continuing operations | $2402 | $(1612) |
| &nbsp;&nbsp;Net loss from discontinued operations | (248) | (1881) |
| Net income (loss) | $2154 | $(3493) |

---

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

***Comparison of the Three Months Ended March 31, 2026 and 2025***

***Revenue***

Disaggregated revenue by segment was as follows:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Logistics: |  |  |  |
| &nbsp;&nbsp;Logistics | $47599 | $35948 | 32.4% |
| Clinical: |  |  |  |
| &nbsp;&nbsp;Transplant Clinical | $9839 | $— | NM(1) |
| &nbsp;&nbsp;Other Clinical | 9946 |  | NM(1) |
| Total Clinical | $19785 | $— | NM(1) |
| **Total Revenue** | $67384 | $35948 | 87.4% |

---

(1) Percentage not meaningful.

For the three months ended March 31, 2026 and 2025, revenue increased by $31.4 million, or 87.4%, from $35.9 million in 2025 to $67.4 million in 2026.

Logistics revenue increased by $11.7 million, or 32.4%, from $35.9 million in 2025 to $47.6 million in 2026, driven by growth in flight hours with increased revenue per flight hour and ground transportation. The increase in flight hours is attributable to both existing and new clients, with several major new contracted clients commencing operations in the second quarter of the year 2025.

Clinical revenue was $19.8 million in the current year period, reflecting the acquisition of Keystone in mid-September 2025. There was no clinical revenue in the prior year period. Current-year clinical revenue consisted of transplant clinical revenue of $9.8 million and other clinical revenue of $9.9 million.

***Gross Profit and Gross Margin***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Gross profit: |  |  |  |
| &nbsp;&nbsp;Logistics | $9165 | $7053 | 29.9% |
| &nbsp;&nbsp;Clinical | 4952 |  | NM(1) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total gross profit | $14117 | $7053 | 100.2% |
| Gross margin: |  |  |  |
| &nbsp;&nbsp;Logistics | 19.3% | 19.6% |  |
| &nbsp;&nbsp;Clinical | 25.0% |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total gross margin | 21.0% | 19.6% |  |

---

(1) Percentage not meaningful.

For the three months ended March 31, 2026 and 2025, Logistics gross profit increased by $2.1 million, or 29.9%, from $7.1 million in 2025 to $9.2 million in 2026, attributable to the 32.4% increase in revenue, partially offset by a small decline in gross margin from 19.6% in 2025 to 19.3% in 2026. For the three months ended March 31, 2026, Clinical gross profit was $5.0 million with a gross margin of 25.0%, attributable to the acquisition of Keystone in mid-September 2025.

Total gross margin increased from 19.6% in 2025 to 21.0% in 2026, attributable primarily to the acquisition of Keystone in mid-September 2025, which operates at a higher average gross margin.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

***Selling, General and Administrative***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| General and administrative staff and related costs | $5761 | $5209 | 10.6% |
| Selling and marketing including staff costs | 584 | 223 | 161.9% |
| Software development including staff costs | 1118 | 719 | 55.5% |
| Professional fees | 1828 | 1201 | 52.2% |
| Facilities and insurance | 1212 | 1108 | 9.4% |
| Stock-based compensation | 5035 | 3809 | 32.2% |
| Depreciation and impairment of property and equipment | 67 | 61 | 9.8% |
| &nbsp;&nbsp;Total selling, general and administrative | $15605 | $12330 | 26.6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percentage of revenue | 23% | 34% |  |

---

For the three months ended March 31, 2026 and 2025, total selling, general and administrative expense increased by $3.3 million, or 26.6%, from $12.3 million in 2025 to $15.6 million in 2026.

The primary drivers of the increase were: (i) a $0.6 million increase in general and administrative staff and related costs attributable to the acquisition of Keystone in mid-September contributing $0.7 million, partially offset by the transfer of certain headquarters employees in connection with the sale of the Passenger business in the third quarter of 2025; (ii) a $0.4 million increase in selling and marketing attributable to the acquisition of Keystone and higher sales commissions; (iii) a $0.4 million increase in software development including staff costs driven by the integration of Keystone's software as well as software application costs incurred to separate our software from the Passenger platform; (iv) a $0.6 million increase in professional fees, driven by M&A-related transaction costs associated with potential acquisitions, as well as reorganization and restructuring costs following the sale of the Passenger business, including integration costs related to Keystone; and (v) a $1.2 million increase in stock-based compensation, driven by new PSUs granted in the past 12 months.

***Amortization of intangible assets***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Amortization of intangible assets | $1486 | $408 | 264.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Percentage of revenue | 2% | 1% |  |

---

For the three months ended March 31, 2026 and 2025, amortization of intangible assets increased by $1.1 million, or 264.2%, from $0.4 million in 2025 to $1.5 million in 2026, attributable to amortization of intangibles generated from the acquisition of Keystone in mid-September 2025.

***Other Non-Operating Income***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Interest income, net | $473 | $1321 |  |
| Change in fair value of warrant liabilities | 1459 | 2752 |  |
| Change in fair value of assets and other liabilities | 3444 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Total other non-operating income | $5376 | $4073 | 32.0% |

---

For the three months ended March 31, 2026, total other non-operating income consisted of: (i) $0.5 million interest income, net primarily attributable to our short-term investments and our money market funds in the current year period (lower interest income is attributable to lower invested balances compared to the prior year period); (ii) $1.5 million non-cash income due to fair value revaluation of warrant liabilities as the value of the warrant liabilities fluctuates with the warrants' market price; and (iii) $3.4

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

million of non-cash income from the remeasurement of assets and liabilities carried at fair value each reporting period, primarily driven by changes in the Company's share price affecting a financial liability settled in equity.

For the three months ended March 31, 2025, total other non-operating income consisted of: (i) $1.3 million interest income, attributable to short-term investments and money market funds; and a (ii) $2.8 million non-cash income due to fair value revaluation of warrant liabilities as the value of the warrant liabilities fluctuates with the warrants' market price.

***Loss from discontinued operations, net of tax***

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Net loss from discontinued operations | $(248) | $(1881) | (87)% |

---

For the three months ended March 31, 2026, net loss from discontinued operations was $(0.2) million, consisting of a post-closing net working capital adjustment on the sale of the Passenger business of $0.3 million, net of tax benefit of $(0.1) million.

For the three months ended March 31, 2025, net loss from discontinued operations was $(1.9) million, consisting of operating loss before tax of $(1.9) million attributable to the Passenger business operations in the United States and Europe.

***Adjusted EBITDA***

The following table presents our consolidated results on a continuing operations basis for Adjusted EBITDA:

---

| | | | |
|:---|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** | |
| | **2026** | **2025** |<br>**% Change** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| Adjusted EBITDA (1) | $6410 | $416 | 1441% |

---

(1) See section below "Reconciliations of Non-GAAP Financial Measures" for more information and a reconciliation to the most directly comparable GAAP financial measure.

***Comparison of the Three Months Ended March 31, 2026 and 2025***

Adjusted EBITDA from continuing operations improved by $6.0 million for the three months ended March 31, 2026 from $0.4 million in 2025 to $6.4 million in 2026. The improvement is attributable to a $7.1 million increase in gross profit, partially offset by a $1.8 million increase in fixed costs, primarily driven by the addition of Keystone, acquired in mid-September 2025.

**Reconciliation of Non-GAAP Financial Measures**

Adjusted EBITDA is a non-GAAP measure that has been derived from amounts calculated in accordance with GAAP, although it is not itself a GAAP measure. Strata believes that Adjusted EBITDA viewed in addition to and not in lieu of our reported U.S. GAAP results, provide useful information to investors by providing a more focused measure of operating results, enhancing the overall understanding of past financial performance and future prospects, and allowing for greater transparency with respect to a key metric used by management in its financial and operational decision making. The non-GAAP measure presented herein may not be comparable to similarly titled measures presented by other companies. Adjusted EBITDA is defined and reconciled to the nearest GAAP financial measure below.

*Adjusted EBITDA*

Defined as net income (loss) from continuing operations adjusted to exclude: (1) depreciation and amortization; (2) stock-based compensation; (3) change in fair value of warrant liabilities and other assets and liabilities; (4) interest income and expense; (5) income tax; and (6) certain other non-recurring items (shown below) that management does not believe are indicative of the Company's ongoing operating performance and would impact the comparability of results between periods.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
|  | *(in thousands, except percentages)* | *(in thousands, except percentages)* |
| **Net income (loss) from continuing operations** | $**2402** | $**(1612)** |
| Add (deduct): |  |  |
| Depreciation and amortization | 3060 | 1224 |
| Stock-based compensation | 5035 | 3809 |
| Change in fair value of warrant liabilities | (1459) | (2752) |
| Change in fair value of assets and other liabilities | (3444) |  |
| Interest income, net | (473) | (1321) |
| Legal expenses and regulatory advocacy fees (1) | 209 | 358 |
| M&A transaction costs and integration of the acquired company (2) | 650 | 17 |
| Reorganization and rebranding costs related to the sale of the Passenger business (3) | 419 |  |
| Corporate staff costs included in the sold Passenger business (4) |  | 693 |
| Other | 11 |  |
| **Adjusted EBITDA** | $**6410** | $**416** |
| Revenue | $67384 | $35948 |
| Adjusted EBITDA as a percentage of revenue | 9.5% | 1.2% |

---

(1) For the three months ended March 31, 2026, mainly includes settlement fees related to one specific legal matter. For the three months ended March 31, 2025, comprised of legal fees related to the *Drulias* class action lawsuit which the parties entered into a Stipulation of Settlement to fully resolve the matter in December 2025. We consider those matters to be non-recurring and not representative of the legal and regulatory advocacy costs typically incurred in the ordinary course of business.

(2) For the three months ended March 31, 2026, consists of M&A transaction costs (including legal fees and professional fees related to financial, legal, and tax due diligence) for potential acquisitions; and costs of integrating Keystone into a public company environment, including enterprise resource planning migration and software development costs to enhance its internally developed software to meet internal control standards.

(3) For the three months ended March 31, 2026, consists of rebranding costs related to the decommissioning of the Blade brand and the introduction of the Strata brand; one-time reorganization costs related to the restructuring of Strata headquarters following the transfer of certain positions to Joby Aviation; and software application costs incurred to separate our software from the Passenger platform.

(4) Represents corporate staff costs related to employees who transferred to Joby Aviation following the sale of the Passenger business on August 29, 2025. This adjustment is intended to enhance period-to-period comparability by excluding from all periods, costs associated with transferred employees whose corporate functions were not replaced. Under U.S. GAAP (ASC 205-20), these costs were required to remain in continuing operations prior to the divestiture because they were not directly attributable to discontinued operations.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**Liquidity and Capital Resources**

***Sources of Liquidity***

As of March 31, 2026 and December 31, 2025, we had total liquidity of $58.8 million and $61.2 million, respectively, consisting of cash and cash equivalents of $58.7 million and $31.0 million, respectively, and short-term investments of $0.1 million and $30.3 million, respectively. In addition, as of March 31, 2026 and December 31, 2025, we had restricted cash of $0.3 million and $0.3 million, respectively. The Company had net income of $2.2 million for the three months ended March 31, 2026.

With $58.8 million of total liquid funds as of March 31, 2026, we anticipate that we have sufficient funds to meet our current operational needs for at least the next 12 months from the date this Quarterly Report is filed. Although we have not historically relied on external sources of financing to help fund our operational needs, in January 2026 we entered into a revolving credit facility (the "ABL Facility") backed by our accounts receivable, that provides additional liquidity and financial flexibility. This facility provides for borrowings of up to $30.0 million and includes an accordion feature permitting increases of up to an additional $20.0 million, subject to lender consent and other conditions. The ABL Facility matures on January 30, 2029.

Borrowings under the ABL Facility bear interest, at the Company's election, at either (i) an adjusted term Secured Overnight Financing Rate ("SOFR") plus an applicable margin of 2.00% or (ii) a floating SOFR-based rate plus an applicable margin of 2.00%. The Company is also required to pay a commitment fee of 0.25% per annum on the unused portion of the facility. For further information on the ABL Facility, refer to Note 16 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.

***Liquidity Requirements***

As of March 31, 2026, the Company had net working capital of $103.2 million, cash and cash equivalents of $58.7 million, and short-term investments of $0.1 million.

In the course of our business, we have certain contractual relationships with third-party aircraft operators pursuant to which we may be contingently required to make payments in the future. As of March 31, 2026, we had commitments to purchase flights from various aircraft operators with aggregate minimum flight purchase guarantees under CPAs of $2.3 million for the year ending December 31, 2026. See "—Capacity Purchase Agreements" within Note 12 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for additional information. Additionally, the Company has operating lease obligations related to real estate and vehicles with expected annual minimum lease payments of $0.7 million and $1.1 million for the years ending December 31, 2026 and 2027, respectively.

We may be required to make earn-out payments in connection with the acquisition of Keystone Perfusion Services, LLC, and may be entitled to receive earn-out proceeds in connection with the Passenger business divestiture. The fair value of the related contingent consideration assets and liabilities is included in the unaudited interim condensed consolidated balance sheets.

Based on our current liquidity, we believe that no additional capital will be needed to execute our current business plan over the next 12 months. Our longer-term liquidity requirement will depend on many factors including the pace of our expansion into new markets, our ability to attract and retain customers for our existing services, capital expenditures, and acquisitions.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

***Cash Flows***

The cash flows of the discontinued Passenger business have not been separately presented and are included in the unaudited interim condensed consolidated statements of cash flows and the discussions below for all periods presented.

For 2025, Passenger cash flows are reflected from January 1 through the August 29, 2025 divestiture date, after which the related assets and liabilities were derecognized. Cash flows of Keystone are included beginning on the September 16, 2025 acquisition date. As a result, period-over-period changes may not be directly comparable.

The following table summarizes our cash flows for the periods indicated:

---

| | | |
|:---|:---|:---|
| | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
| | **2026** | **2025** |
|  | *(in thousands)* | *(in thousands)* |
| Net cash provided by / (used in) operating activities | $3885 | $(246) |
| Net cash provided by investing activities | 24729 | 20407 |
| Net cash used in financing activities | (859) | (4246) |
| Effect of foreign exchange rate changes on cash balances |  | 126 |
| Net increase in cash and cash equivalents and restricted cash | $27755 | $16041 |

---

*Cash Provided by / (Used In) Operating Activities*

For the three months ended March 31, 2026, net cash provided by operating activities was $3.9 million, driven by net income of $2.2 million, adjusted for net non-cash items of $3.2 million and $1.5 million net cash used by changes in working capital assets and liabilities. The $1.5 million net cash used by changes in working capital assets and liabilities was primarily driven by: a decrease of $2.2 million in accounts payable and accrued liabilities driven by the payment of the 2025 short term incentive plan; partially offset by a decrease of $0.1 million in accounts receivable and a decrease of $0.4 million in prepaid and other current assets driven by timing of operator prepayments.

For the three months ended March 31, 2025, net cash used in operating activities was $0.2 million, driven by a net loss of $3.5 million and $0.7 million of net cash provided by changes in working capital assets and liabilities, adjusted for net non-cash items of $2.5 million. The $0.7 million of net cash provided by changes in working capital assets and liabilities was primarily driven by a decrease in prepaid expenses and other current assets of $2.3 million driven by timing of prepayments to Passenger business operators and an increase in deferred revenue of $1.3 million attributable to Passenger business retail customers prepayments, partially offset by a decrease in accounts payable and accrued expenses of $2.3 million, driven by the payment of the 2024 short term incentive plan and an increase in accounts receivable of $0.5 million.

*Cash Provided by Investing Activities*

For the three months ended March 31, 2026, net cash provided by investing activities was $24.7 million, driven by $30.5 million of proceeds from maturities of held-to-maturity investments; offset by $5.2 million in purchases of property and equipment, driven primarily by $3.7 million for the acquisition of an aircraft and $0.8 million of capitalized maintenance costs of the existing fleet; $0.3 million in capitalized software development costs; and $0.3 million in cash transferred with the sale of the Passenger business, driven by the final net working capital adjustment payment to the buyer.

For the three months ended March 31, 2025, net cash provided by investing activities was $20.4 million, driven by $107.8 million of proceeds from maturities of held-to-maturity investments; offset by $84.2 million in purchases of held-to-maturity investments, $2.6 million in purchases of property and equipment, consisting primarily of a spare engine and aircraft related capitalized maintenance costs for our fleet; and $0.5 million in capitalized software development costs, primarily for the Passenger app.

*Cash Used In Financing Activities*

For the three months ended March 31, 2026, net cash used in financing activities was $0.9 million, driven by $0.6 million in cash paid for payroll tax payments on behalf of employees in exchange for shares withheld by the Company and $0.3 million of debt issuance costs incurred with establishing the ABL Facility.

For the three months ended March 31, 2025, net cash used in financing activities was $4.2 million, reflecting $4.3 million in cash paid for payroll tax payments on behalf of employees in exchange for shares withheld by the Company.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**Critical Accounting Policies and Significant Judgments and Estimates**

This discussion and analysis of the Company's financial condition and results of operations is based on the Company's unaudited interim condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP. The preparation of these unaudited interim condensed financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. In accordance with U.S. GAAP, the Company bases its estimates on historical experience and on various other assumptions the Company believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

For information on the Company's significant accounting policies and estimates refer to "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Estimates" in our Annual Report on Form 10-K for the year ended December 31, 2025. There have been no material changes to these policies and estimates as of March 31, 2026.

**Item 3. Quantitative and qualitative disclosures about market risk**

Our primary market risk exposure is interest rate risk related to potential borrowings. Borrowings under our ABL Facility bear interest at a variable rate based on SOFR plus an applicable margin as described in Note 16 to the unaudited interim condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. As of March 31, 2026, there were no outstanding borrowings under the ABL Facility and accordingly our earnings and cash flows would not have been materially impacted by a hypothetical change in interest rates.

We do not have material exposure to foreign currency exchange rate risk as our operations are conducted entirely within the United States following the sale of our Passenger business in August 2025.

**Item 4. Controls and Procedures** 

***Evaluation of Disclosure Controls and Procedures***

As of the end of the period covered by this report, our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based on their evaluation of our disclosure controls and procedures, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2026 to provide reasonable assurance that information required to be disclosed by the Company in the reports that we file or submit under the Exchange Act is (a) recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and (b) accumulated and communicated to management, including our principal executive officer and principal financial officer, as appropriate to allow for timely decisions regarding required disclosure.

***Changes in Internal Control over Financial Reporting***

There were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Securities Exchange Act of 1934, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting during the period covered by this Quarterly Report on Form 10-Q.

***Limitations on Internal Control over Financial Reporting***

An internal control system over financial reporting has inherent limitations and may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**PART II - OTHER INFORMATION**

**Item 1. Legal Proceedings**

See "—Legal and Environmental" within Note 12 to the unaudited interim condensed consolidated financial statements in Part I, Item 1 for information on legal proceedings.

**Item 1A. Risk Factors**

There have been no material changes to the risks described under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025. You should carefully consider these risks as they could materially affect our business, results of operations or financial condition, cause the trading price of our common stock to decline materially or cause our actual results to differ materially from those expected or those expressed in any forward-looking statements made by, or on behalf of, the Company. These risks are not exclusive, and additional risks to which we are subject include, but are not limited to, the factors mentioned under "Forward-Looking Statements" and the risks of our businesses described elsewhere in this Quarterly Report on Form 10-Q.

**Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities**

Not applicable.

**Item 3. Defaults Upon Senior Securities**

Not applicable.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other information**

None.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1<sup>(1)</sup> | <u>[Second Amended and Restated Certificate of Incorporation of Blade Air Mobility, Inc.](https://www.sec.gov/Archives/edgar/data/0001779128/000110465921065292/tm2115701d2_ex3-1.htm)</u> |
| 3.2<sup>(2)</sup> | <u>[Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation of Blade Air Mobility, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085185/tm2524340d2_ex3-1.htm)</u> |
| 3.3<sup>(3)</sup> | <u>[Amended and Restated Bylaws of Strata Critical Medical, Inc.](https://www.sec.gov/Archives/edgar/data/1779128/000110465925085185/tm2524340d2_ex3-2.htm)</u> |
| 10.1<sup>(4)</sup> | <u>[Credit Agreement, dated as of January 30, 2026, among Strata Critical Medical, Inc., Strata Critical, Inc., Trinity Air Medical, LLC, Keystone Perfusion Services, LLC, the other Loan Parties party thereto, the Lenders party thereto, and JPMorgan Chase Bank, N.A., as Administrative Agent](https://www.sec.gov/Archives/edgar/data/1779128/000110465926010689/tm265039d1_ex10-1.htm)</u> |
| 10.2<sup>(5)</sup> | <u>[Pledge and Security Agreement, dated as of January 30, 2026, by and among Strata Critical Medical, Inc., Strata Critical, Inc., Trinity Air Medical, LLC, Keystone Perfusion Services, LLC, and any additional entities which become parties thereto, and JPMorgan Chase Bank, N.A., in its capacity as Administrative Agent](https://www.sec.gov/Archives/edgar/data/1779128/000110465926010689/tm265039d1_ex10-2.htm)</u> |
| 31.1\* | <u>[Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](srta-ex311xq12026.htm)</u> |
| 31.2\* | <u>[Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](srta-ex312xq12026.htm)</u> |
| 32.1\* | <u>[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002](srta-ex321xq12026.htm)</u> |
| 32.2\* | <u>[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes- Oxley Act of 2002](srta-ex322xq12026.htm)</u> |
| 101.INS\* | Interactive Data Files pursuant to Rule 405 of Regulation S-T formatted in Inline Extensible Business Reporting Language ("Inline XBRL") |
| 101.CAL\* | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.SCH\* | XBRL Taxonomy Extension Schema Document |
| 101.DEF\* | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | XBRL Taxonomy Extension Labels Linkbase Document |
| 101.PRE\* | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |

---

_______________________________

\*Filed herewith

(1)Incorporated by reference to Exhibit 3.1 of our Form 8-K (file number 001-39046) filed on May 13, 2021.

(2)Incorporated by reference to Exhibit 3.1 of our Form 8-K (file number 001-39046) filed on August 29, 2025.

(3)Incorporated by reference to Exhibit 3.2 of our Form 8-K (file number 001-39046) filed on August 29, 2025.

(4)Incorporated by reference to Exhibit 10.1 of our Form 8-K (file number 001-39046) filed on February 5, 2026.

(5)Incorporated by reference to Exhibit 10.2 of our Form 8-K (file number 001-39046) filed on February 5, 2026.

(6)This exhibit shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such exhibit shall not be deemed incorporated into any filing under the Securities Act or the Exchange Act.

------

<u>[**Table of Contents**](#i478d476b6c9945bc916cef5843252416_13)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **STRATA CRITICAL MEDICAL, INC.** | **STRATA CRITICAL MEDICAL, INC.** |
| Date: May 6, 2026 | By: | /s/ Melissa Tomkiel |
|  | Name: | Melissa Tomkiel |
|  | Title: | Co-Chief Executive Officer<br>(Principal Executive Officer) |
| Date: May 6, 2026 | By: | /s/ William A. Heyburn |
|  | Name: | William A. Heyburn  |
|  | Title: | Co-Chief Executive Officer and Chief Financial Officer<br>(Principal Executive & Financial Officer) |
| Date: May 6, 2026 | By: | /s/ Amir M. Cohen |
|  | Name: | Amir M. Cohen |
|  | Title: | Chief Accounting and Integration Officer<br>(Principal Accounting Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

**PURSUANT TO RULE 13a-14 AND 15d-14**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED**

I, Melissa M. Tomkiel, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strata Critical Medical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 6, 2026 | By: | /s/ Melissa M. Tomkiel |
|  | Name: | Melissa M. Tomkiel |
|  | Title: | Co-Chief Executive Officer (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

**PURSUANT TO RULE 13a-14 AND 15d-14**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED**

I, William A. Heyburn, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Strata Critical Medical, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: May 6, 2026 | By: | /s/ William A. Heyburn |
|  | Name: | William A. Heyburn |
|  | Title: | Co-Chief Executive Officer and Chief Financial Officer (Principal Executive and Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Strata Critical Medical, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), I, Melissa M. Tomkiel, Co-Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

---

| | | |
|:---|:---|:---|
| Date: May 6, 2026 | By: | /s/ Melissa M. Tomkiel |
|  | Name: | Melissa M. Tomkiel |
|  | Title: | Co-Chief Executive Officer<br>(Principal Executive Officer) |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Strata Critical Medical, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2026, as filed with the Securities and Exchange Commission (the "Report"), I, William A. Heyburn, Co-Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.

---

| | | |
|:---|:---|:---|
| Date: May 6, 2026 | By: | /s/ William A. Heyburn |
|  | Name: | William A. Heyburn |
|  | Title: | Co-Chief Executive Officer and Chief Financial Officer<br>(Principal Executive and Financial Officer) |

---

<br>